Trelegy Ellipta(Fluticasone/Umeclidin/Vilanter)
GSK
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by GSK plc
$5.29B
Medicare cost, 2024
$5.29B
Medicare cost, 2024
Medicare drug plans spent $5.3 billion on Trelegy Ellipta (fluticasone/umeclidin/vilanter) in 2024, for 6.2 million prescriptions and refills filled by 1.3 million patients. It ranks 7th among all drugs by Medicare drug plan spending. Spending rose 19% from 2023 to 2024. Florida accounts for the most spending ($428.0 million, 8% of the total).
Medicare cost, 2024
$5.29B
+18.8% from 2023
Prescriptions
6.2M
$847.00 per claim
Patients
1.3M
237,439 prescribers
Total spending, 2024
$5.29B
$4,172.39 per patient
Questions and answers
How much does Medicare spend on Trelegy Ellipta?
Medicare prescription drug plans paid $5.29B for Trelegy Ellipta in 2024, for 6,248,740 prescriptions and refills to 1,268,461 patients (up 18.8% from 2023). The average cost per claim was $847.00.
Which state spends the most on Trelegy Ellipta?
Florida had the highest Medicare cost for Trelegy Ellipta in 2024: $428.0M for 473,878 claims, followed by New York ($353.5M).
Who prescribes Trelegy Ellipta the most?
Jorge Sanchez-Masiques, pulmonary disease in Miami, FL, had the highest Medicare cost for Trelegy Ellipta in 2024: 3,564 claims costing $2.4M.
Who makes Trelegy Ellipta?
Trelegy Ellipta is made by GSK plc (GSK), listed in the Medicare spending data as Glaxosmithkline.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Trelegy Ellipta was $5.29B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Trelegy Ellipta, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Jorge Sanchez-Masiques Miami, FL | Pulmonary Disease | 3,564 | 683 | $2.4M |
| Kaiser Toosy New Haven, CT | Pulmonary Disease | 2,514 | 466 | $2.3M |
| Jason B Karp Lake Success, NY | Pulmonary Disease | 1,722 | 533 | $2.0M |
| Michael A Imevbore New Haven, CT | Pulmonary Disease | 1,541 | 443 | $1.9M |
| Ernesto Mejia Morristown, TN | Pulmonary Disease | 2,304 | 529 | $1.8M |
| Rajesh Agrawal Pinellas Park, FL | Pulmonary Disease | 2,210 | 524 | $1.7M |
| Ladly Abraham Conway, AR | Pulmonary Disease | 2,033 | 389 | $1.6M |
| Ahmed S Bhatti Granbury, TX | Pulmonary Disease | 2,065 | 434 | $1.6M |
| Morgan G Miller Rocky Mount, NC | Nurse Practitioner | 1,775 | 385 | $1.6M |
| Elizabeth M Kluka Kalamazoo, MI | Critical Care (Intensivists) | 2,139 | 383 | $1.6M |
| Ashesh D Desai Conroe, TX | Pulmonary Disease | 1,298 | 369 | $1.5M |
| Rafael A Martinez Tampa, FL | Pulmonary Disease | 2,001 | 448 | $1.5M |
| Fernando L Martinez Catinchi Hialeah, FL | Pulmonary Disease | 2,264 | 708 | $1.5M |
| Ajay D Deshpande Terre Haute, IN | Pulmonary Disease | 1,736 | 404 | $1.4M |
| Hoang T Le Fountain Valley, CA | Pulmonary Disease | 1,648 | 283 | $1.4M |
| Richard A Miller Newark, NJ | Pulmonary Disease | 1,874 | 359 | $1.4M |
| Lohaliz Bobe Port Charlotte, FL | Pulmonary Disease | 1,405 | 312 | $1.4M |
| Walid F Tanyous Venice, FL | Pulmonary Disease | 979 | 340 | $1.3M |
| Gary R Schafer Forest City, NC | Pulmonary Disease | 1,703 | 314 | $1.3M |
| Ahmad M Ibrahimbacha Cleveland, TN | Pulmonary Disease | 1,836 | 330 | $1.3M |
| Alec J Steils Waterloo, IA | Nurse Practitioner | 1,456 | 310 | $1.3M |
| Stephen G Basheda Pittsburgh, PA | Pulmonary Disease | 1,833 | 312 | $1.3M |
| Gaurav Sangwan Springfield, IL | Pulmonary Disease | 1,618 | 267 | $1.3M |
| Rohit G Patel Anniston, AL | Pulmonary Disease | 1,766 | 325 | $1.3M |
| Wendi Shaffmaster Richmond, IN | Nurse Practitioner | 1,531 | 289 | $1.3M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 175,214 | 3,925,466 | 833,805 | $3.34B |
| 2023 | 208,099 | 5,007,613 | 1,049,967 | $4.45B |
| 2024 | 237,439 | 6,248,740 | 1,268,461 | $5.29B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Glaxosmithkline | 6,250,872 | $5.29B |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.